Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

5124ATA129-EBV-302-NCT03394365OpenMulticenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy ATA129-EBV-302NCT03394365IndustrialBothTreatmentIIILymphoid LeukemiaEkong, UdemeGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterPediatricsOncology GroupGUMC Transplant2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>